Detection and quantification of protein biomarkers from fewer than 10 cells

被引:36
作者
Nettikadan, S
Radke, K
Johnson, J
Xu, JT
Lynch, M
Mosher, C
Henderson, E
机构
[1] BioForce Nanosci Inc, Ames, IA 50010 USA
[2] Iowa State Univ, Genet Dev & Cell Biol Dept, Ames, IA 50011 USA
[3] Des Moines Univ, Dept Microbiol, Des Moines, IA 50312 USA
关键词
D O I
10.1074/mcp.M500350-MCP200
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The use of antibody microarrays continues to grow rapidly due to the recent advances in proteomics and automation and the opportunity this combination creates for high throughput multiplexed analysis of protein biomarkers. However, a primary limitation of this technology is the lack of PCR-like amplification methods for proteins. Therefore, to realize the full potential of array-based protein biomarker screening it is necessary to construct assays that can detect and quantify protein biomarkers with very high sensitivity, in the femtomolar range, and from limited sample quantities. We describe here the construction of ultramicroarrays, combining the advantages of microarraying including multiplexing capabilities, higher throughput, and cost savings with the ability to screen very small sample volumes. Antibody ultramicroarrays for the detection of interleukin-6 and prostate-specific antigen (PSA), a widely used biomarker for prostate cancer screening, were constructed. These ultramicroarrays were found to have a high specificity and sensitivity with detection levels using purified proteins in the attomole range. Using these ultramicroarrays, we were able to detect PSA secreted from 100 LNCaP cells in 3 h and from just four LNCaP cells in 24 h. Cellular PSA could also be detected from the lysate of an average of just six cells. This strategy should enable proteomic analysis of materials that are available in very limited quantities such as those collected by laser capture microdissection, neonatal biopsy microspecimens, and forensic samples.
引用
收藏
页码:895 / 901
页数:7
相关论文
共 30 条
[1]   Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma [J].
Adler, HL ;
McCurdy, MA ;
Kattan, MW ;
Timme, TL ;
Scardino, PT ;
Thompson, TC .
JOURNAL OF UROLOGY, 1999, 161 (01) :182-187
[2]   Biology of prostate-specific antigen [J].
Balk, SP ;
Ko, YJ ;
Bubley, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :383-391
[3]  
Chung TDK, 1999, PROSTATE, V38, P199
[4]  
Ekins R.P., 1998, NANOBIOLOGY, V4, P197
[5]   Androgen receptor signaling in androgen-refractory prostate cancer [J].
Grossmann, ME ;
Huang, HJ ;
Tindall, DJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (22) :1687-1697
[6]  
Haab BB, 2001, GENOME BIOL, V2
[7]  
HENDERSON E, 2003, Patent No. 6573369
[8]   Prostate-specific antigen:: A review of the validation of the most commonly used cancer biomarker [J].
Hernández, J ;
Thompson, IM .
CANCER, 2004, 101 (05) :894-904
[9]  
Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO
[10]  
2-6